In This Article:
-
Revenue: Increased by 56% compared to the prior year.
-
Adjusted EBITDA: Improved by 70% to $99 million.
-
Operating Cash Inflow: Improved by 80%.
-
Profit After Tax: Increased by 860%.
-
End of Year Cash Position: $710 million, bolstered by a convertible bond placement.
-
R&D Investment: $195 million, focusing on regulatory filings and inventory scale-up.
-
Gross Margin: Improved by 3% to 65%.
-
Precision Medicine Revenue Growth: 55% increase in sales of Aleix.
-
Therapeutic Pipeline Investment: Increased by 74% to $82 million.
-
Manufacturing Expansion: Incremental increase of $19 million in operating expenses due to acquisitions and facility expansion.
-
2025 Revenue Guidance: Approximately $1.2 billion AUD or $770 to $800 million USD.
Release Date: February 20, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Telix Pharmaceuticals Ltd (TLPPF) reported a 56% increase in revenue, surpassing guidance.
-
The company achieved a 70% improvement in adjusted EBIT, reaching $99 million.
-
Telix Pharmaceuticals Ltd (TLPPF) saw an 80% improvement in operating cash inflow.
-
Profit after tax improved by 860%, showcasing strong financial performance.
-
The company ended the year with a solid cash position of $710 million, bolstered by a convertible bond placement.
Negative Points
-
The company faces uncertainties in the US healthcare system, which could impact future growth.
-
Regulatory approval delays in the US could affect the launch of new products.
-
The expiration of CMS pass-through status for Eustic could impact revenue in the second half of 2025.
-
There is a risk of market cannibalization between new and existing products.
-
The company has not yet included potential revenue from new product launches and territories in its guidance, indicating uncertainty in future financial projections.
Q & A Highlights
Q: What is the expected revenue growth for Telix Pharmaceuticals' RLS division in 2025? A: Christian Behrenbruch, Group CEO, stated that the revenue guidance includes 11 months of RLS Radio Pharma. The company expects high single-digit to low double-digit growth across the US business, inclusive of Eluix and RLS, reflecting continued expansion opportunities for PSMA and considering some headwinds in the US healthcare system.
Q: How does Telix Pharmaceuticals view the market growth for US PSMA sales in 2025? A: Christian Behrenbruch noted that the expansion of the PSMA opportunity continues, with new indications and opportunities potentially causing step changes in market growth. The launch of Gelics is expected to expand market reach and accelerate growth, particularly in the second half of the year.